References
- EisingerSHMeldrumSFiscellaKle RouxHDGuzickDSLow-dose mifepristone for uterine leiomyomataObstet Gynecol2003101224325012576246
- EisingerSHBonfiglioTFiscellaKMeldrumSGuzickDSTwelve-month safety and efficacy of low-dose mifepristone for uterine myomasJ Min Invasiv Gynecol2005123227233
- EisingerSHFiscellaJBonfiglioTMeldrumSFiscellaKOpen-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomataEur J Obstet Gynecol20091462215218
- FiscellaKEisingerSHMeldrumSFengCFisherSGGuzickDSEffect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. A randomized controlled trialObstet Gynecol200610861381138717138770
- Carbonell EsteveJLAcostaRHerediaBPérezYCastañedaMCHernándezAVMifepristone for the treatment of uterine leiomyomasObstet Gynecol200811251029103618978102
- Carbonell JL, Quiróz Rámirez GM, Borge A, Castellón Zapata LE, Cuadra Aragón W, Giuseppe Tomasi G. [Mifepristone 5 mg versus 10 mg daily to treat leiomyoma]Prog Obstet Ginecol20091018 Spanish
- CarbonellJLAcostaRPérez Y, Yero MC, Seigler I, Heredia B. [Evolution of uterine leiomyoma after treatment with mifepristone. Randomized clinical trial]Prog Obstet Ginecol2010536231236 Spanish
- CarbonellJLAcostaRHerediaB[Mifepristone to treat uterine fibroids]Rev Cub Gynecol Salud Reprod2010362 Spanish
- EsteveJLAcostaRPérezYCamposRHernándezAVTexidóCSTreatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trialEur J Obstet Gynecol Reprod Biol2012161220220822269473
- Carbonell EsteveJLRiverónAMCanoMMifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgeryInt J Womens Health20124758422448109
- CarbonellJLAcostaRPérezYSafety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trialInt J Womens Health2013511512423658500
- EngmanMGranbergSWilliamsARMengCXLalitkumarPGGemzell-DanielssonKMifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trialHum Reprod20092481870187919389793
- http://www.ema.europa.euEPAR summary for the public Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002041/WC500124089.pdfAccessed April 3, 2013
- FiscellaFBonfiglioTWintersPEisingerSHFiscellaKDistinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristoneHum Pathol201142794795321315422
- BagariaMSunejaAVaidNBGuleriaKMishraKLow-dose mife-pristone in treatment of uterine leiomyoma: a randomized double-blind placebo-controlled trialAust N Z J Obstet Gynaecol2009491778319281585
- Management of Uterine Fibroids AHRQ Publication NO 01-E051. Evidence report/technology assessment: Number 34Rockville, MDAgency for Healthcare Research and Quality2001 Available from: http://archive.ahrq.gov/clinic/epcsums/utersumm.htmAccessed May 11, 2012
- HorneFMBlitheDLProgesterone receptor modulators and the endometrium: changes and consequencesHum Reprod Update200713656758017630398
- MutterGLBergeronCDeligdischLThe spectrum of endometrial pathology induced by progesterone receptor modulatorsMod Pathol200821559159818246050
- SpiesJBCoyneKGuaou GuaouNBoyleDSkyrnarz-MurphyKGonzalvesSMThe UFS-QOL, a new disease-specific and health-related quality of life questionnaire for leiomyomaObstet Gynecol200299229030011814511